Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18686228 | 1.00 | AGTR1 (0.40) | AGTR1AGTR2RARBTLR7HCAR2 | |
| SCHEMBL1978411 | 0.93 | AGTR1 (0.44) | AGTR1AGTR2ALDH1A1POLBKMT2A | |
| SCHEMBL28236700 | 0.89 | TLR7 (0.40) | AGTR1AGTR2RARBTLR7ALDH1A1 | |
| SCHEMBL12199191 | 0.84 | LPO (0.40) | AGTR1AGTR2TLR7ALDH1A1POLB | |
| SCHEMBL28701458 | 0.82 | FDPS (0.39) | ALDH1A1KMT2A | |
| SCHEMBL4256418 | 0.82 | AGTR1 (0.41) | AGTR1AGTR2TLR7ALDH1A1POLB | |
| SCHEMBL27888203 | 0.81 | FDPS (0.54) | AGTR1AGTR2KMT2ALMNATSHR | |
| SCHEMBL9369991 | 0.81 | FNTA (0.36) | AGTR1AGTR2ALDH1A1POLBKMT2A | |
| SCHEMBL27690028 | 0.80 | AGTR1 (0.41) | AGTR1AGTR2ALDH1A1POLBKMT2A | |
| Acetic Acid SCHEMBL28317766 | 0.79 | FNTA (0.46) | AGTR1AGTR2RARBTLR7HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040483-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2013-01-24 | — | — | US | claimed |
| JP-2011524416-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-2306985-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | Biovascular, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2010005480-A9 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| WO-2010005480-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-01-14 | — | — | WO | claimed |
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | BIOVASCULAR, INC. | 2009-12-31 | — | — | US | claimed |
| US-9700521-B2 | Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-07-11 | — | — | US | disclosed |
| EP-2968135-A1 | MULTI-LAYERED INJECTABLE SELF-ASSEMBLING PEPTIDE SCAFFOLD HYDROGELS FOR LONG-TERM SUSTAINED RELEASE OF HUMAN ANTIBODIES | Massachusetts Institute of Technology (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140302144-A1 | MULTI-LAYERED INJECTABLE SELF-ASSEMBLING PEPTIDE SCAFFOLD HYDROGELS FOR LONG-TERM SUSTAINED RELEASE OF HUMAN ANTIBODIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2014152751-A1 | MULTI-LAYERED INJECTABLE SELF-ASSEMBLING PEPTIDE SCAFFOLD HYDROGELS FOR LONG-TERM SUSTAINED RELEASE OF HUMAN ANTIBODIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | PF4, PLAT, VASP | AGTR1 650/4885AGTR2 763/4885RARB 4767/4885 |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | AGTR1 1252/4885AGTR2 1778/4885RARB 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.